Dr. Carl K. Edwards, III, is Chief Scientific Officer at DNX Biopharmaceuticals, Inc. (San Diego, CA). He has 25+ years’ experience in inflammation, autoimmune, autoinflammation, and infectious diseases biopharmaceutical R&D focused on advancing innovative therapies to commercialization stages. As Senior Scientist (Marion Merrell Dow, Inc.), he led the TNFα inhibitors R&D Discovery Program to the clinic (1991-1994). As Clinical Research Investigator (Amgen, Inc.), Dr. Edwards advanced PEGsunercept®, a second-generation TNFα inhibitor, from discovery to late-stage Rheumatoid Arthritis trials (1994-2003). Dr. Edwards was Pharmacology/Toxicology BLA Team Leader for Kineret® (Interleukin-1 receptor antagonist, IL-Ira), and presented to the FDA Advisory Committee (1998-2001). Denusamab™, developed in the inflammation research group led by Dr. Edwards, was FDA approved for osteoporosis and bone disorders. For these accomplishments, Dr. Edwards was awarded the Amgen Development and Inflammation Scientist of the Year Awards (2002-2003). Dr. Edwards has served as Professor of Medicine, University of Colorado, with faculty appointments in Dermatology, Rheumatology, and Infectious Diseases (2005-Present). Carl established (1) Dermatology’s Psoriasis and Cutaneous Inflammation Laboratory specializing in inflammation, cytokines, adaptive immunity, and (2) founded Western States Biopharmaceuticals, Inc. (Aurora, CO, Beijing, China). Dr. Edwards served as Principal Investigator, Chinese National Human Genome Center (Beijing, China), and Professor of Medicine, Division Head, Immunology, at Sichuan University (Chengdu, China) during his Sabbatical (2010 – 2016). Dr. Edwards served as Head, Preclinical R&D (Amicrobe, Inc.) tasked with advancing novel antimicrobials to treat multi-drug resistant bacteria (2014 – 2017). He continues to maintain his faculty appointment at the University of Colorado.